Innate Pharma (IPHA) Total Non-Current Liabilities (2017 - 2025)
Innate Pharma (IPHA) has disclosed Total Non-Current Liabilities for 8 consecutive years, with $74.0 million as the latest value for Q4 2024.
- For the quarter ending Q4 2024, Total Non-Current Liabilities fell 17.79% year-over-year to $74.0 million, compared with a TTM value of $74.0 million through Dec 2024, down 17.79%, and an annual FY2024 reading of $74.9 million, down 17.18% over the prior year.
- Total Non-Current Liabilities was $74.0 million for Q4 2024 at Innate Pharma, down from $90.0 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $126.3 million in Q4 2020 and bottomed at $74.0 million in Q4 2024.
- Average Total Non-Current Liabilities over 5 years is $97.6 million, with a median of $91.7 million recorded in 2021.
- The sharpest move saw Total Non-Current Liabilities skyrocketed 83.72% in 2020, then decreased 27.4% in 2021.
- Year by year, Total Non-Current Liabilities stood at $126.3 million in 2020, then dropped by 27.4% to $91.7 million in 2021, then increased by 15.48% to $105.9 million in 2022, then dropped by 15.02% to $90.0 million in 2023, then fell by 17.79% to $74.0 million in 2024.
- Business Quant data shows Total Non-Current Liabilities for IPHA at $74.0 million in Q4 2024, $90.0 million in Q4 2023, and $105.9 million in Q4 2022.